0000000000643199

AUTHOR

Massimiliano Alù

showing 5 related works from this author

Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.

2014

e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...

Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2CytotoxicitybusinessJournal of Clinical Oncology
researchProduct

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with …

2016

// Giuseppe Bronte 1, * , Tindara Franchina 2, * , Massimiliano Alu 3, * , Giovanni Sortino 1 , Claudia Celesia 1 , Francesco Passiglia 1 , Giuseppina Savio 3 , Agata Laudani 3 , Alessandro Russo 2 , Antonio Picone 2 , Sergio Rizzo 1 , Michele De Tursi 4 , Elisabetta Gambale 4 , Viviana Bazan 1 , Clara Natoli 4 , Livio Blasi 3 , Vincenzo Adamo 2 , Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Medical Oncology Unit-AOOR Papardo-Piemonte, Messina and Department of Human Pathology, University of Messina, Messina, Italy 3 Medical Oncology Unit, A.R.N.A.S. Civico, Palermo, Italy 4 Department of Medical, Oral and Biotechnological …

Male0301 basic medicineOncologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classEGFRTyrosine kinase inhibitorKaplan-Meier EstimateTyrosine-kinase inhibitorErlotinib Hydrochloride03 medical and health sciences0302 clinical medicineGefitinibCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansChemotherapyErlotinib HydrochlorideLung cancerProtein Kinase InhibitorsChemotherapy EGFR Non-small-cell lung cancer Tyrosine kinase inhibitor OncologyAgedRetrospective StudiesAged 80 and overPerformance statusbusiness.industryChemotherapy; EGFR; Non-small-cell lung cancer; Tyrosine kinase inhibitor; OncologyGefitinibRetrospective cohort studyMiddle Agedmedicine.diseaserespiratory tract diseasesSurgeryErbB ReceptorsClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationQuinazolinesFemaleErlotinibbusinessNon-small-cell lung cancerResearch Papermedicine.drug
researchProduct

Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

2017

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients

0301 basic medicinebusiness.industrymedicine.medical_treatment02 engineering and technologyHematologyImmunotherapyctDNA biomarker NSCLC Nivolumab immunotherapy021001 nanoscience & nanotechnology03 medical and health sciences030104 developmental biologyOncologyCirculating tumor DNACancer researchMedicineBiomarker (medicine)Nivolumab0210 nano-technologybusinessPredictive biomarker
researchProduct

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer

2018

Rossella De Luca,1 Livio Blasi,2 Massimiliano Alù,2 Valerio Gristina,1 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Medical Oncology Unit, ARNAS Hospital Civico, Di Cristina, Benfratelli, Palermo, Italy Purpose: Pancreatic carcinoma is the neoplasia with the major mortality, and main standard treatments in this cancer increase survival but do not lead to complete recovery of the patient. The aim of this study was to evaluate the efficacy of Abraxane® (nab-paclitaxel) in Italian patients with metastatic pancreatic cancer (MPC).Patients and methods: We conducted a retrospective …

Male0301 basic medicineOncologyTime Factorsmedicine.medical_treatmentPharmaceutical ScienceKaplan-Meier EstimatechemotherapyMetastasis0302 clinical medicineRisk FactorsDrug DiscoveryClinical endpointOriginal ResearchMiddle AgedTreatment OutcomeItalyTolerabilityCA 19-9030220 oncology & carcinogenesisFemaleCA19-9medicine.drugmedicine.medical_specialtyCA-19-9 AntigenPaclitaxeloverall survivalPainAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalAbraxane03 medical and health sciencesAlbuminsInternal medicinemedicineHumansmetastasisAbraxane chemotherapy pancreatic carcinoma metastasis CA 19-9 pain overall survivalSurvival rateAgedRetrospective StudiesPharmacologyChemotherapyDrug Design Development and Therapypancreatic carcinomabusiness.industryCancermedicine.diseaseGemcitabinePancreatic Neoplasms030104 developmental biologyLinear ModelsAlbumin-Bound PaclitaxelbusinessDrug Design, Development and Therapy
researchProduct

The role of second-line tyrosine kinase inhibitor monotherapy in EGFR wild-type advanced non-small-cell lung cancer patients: Findings from a retrosp…

2015

e19030 Background: Second-line treatment for advanced non-small-cell lung cancer (aNSCLC) patients includes monotherapy with a third generation cytotoxic drug (CT) or with the tyrosine kinase inhib...

Cancer Researchmedicine.drug_classbusiness.industryWild typePharmacologymedicine.diseaseTyrosine-kinase inhibitorThird generationSecond lineOncologymedicineCancer researchRetrospective analysisNon small cellLung cancerbusinessTyrosine kinaseJournal of Clinical Oncology
researchProduct